Chromatic light therapy for inhibiting myopia progression: human studies

Myopia, a common refractive error, has been associated with various risk factors, with outdoor time emerging as a significant protective factor against its onset. This association is believed to be mediated by the influence of sunlight on dopamine release, a neurotransmitter crucial for regulating eye growth. Recent research explores the specific properties of light to identify potential interventions for myopia control in children. Low-level red light therapy has gained attention, showing promise in inhibiting myopia progression, although with concerns regarding safety and rebound effects. Similarly, blue light stimulation aims to upregulate retinal dopamine activity, yet conclusive evidence supporting its efficacy is lacking. Moreover, researchers explore the use of the entire visible light spectrum by digitally imposing longitudinal chromatic aberration to adjust proper eye growth. Preliminary findings suggest that digitally simulated chromatic aberration could potentially serve as a myopia control strategy, highlighting the need for further investigation into its long-term effects. As research progresses, understanding the efficacy and safety of light-based interventions for myopia control remains crucial for informing clinical practice and optimizing patient outcomes.

Publikationsverlauf

Eingereicht: 08. April 2024

Angenommen nach Revision: 09. Mai 2024

Accepted Manuscript online:
09. Mai 2024